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AbstrACt
Introduction Bladder cancer is the most frequently 
occurring tumour of the urinary system. Ta, T1 tumours and 
carcinoma in situ (CIS) are grouped as non-muscle invasive 
bladder cancer (NMIBC), which can be effectively treated 
by transurethral resection of bladder tumour (TURBT). 
There are limitations to the visualisation of tumours 
with conventional TURBT using white light illumination 
within the bladder. Incomplete resections occur from the 
failure to identify satellite lesions or the full extent of the 
tumour leading to recurrence and potential risk of disease 
progression. To improve complete resection, photodynamic 
diagnosis (PDD) has been proposed as a method that 
can enhance tumour detection and guide resection. The 
objective of the current research is to determine whether 
PDD-guided TURBT is better than conventional white light 
surgery and whether it is cost-effective.
Methods and analysis PHOTO is a pragmatic multicentre 
randomised controlled trial (open parallel group, non-
masked and superiority trial) comparing the intervention 
of PDD-guided TURBT with standard white light resection 
in newly diagnosed intermediate and high risk NMIBC 
within the UK National Health Service setting. Clinical 
effectiveness is measured with time to recurrence. Cost-
effectiveness is assessed within trial via the calculation of 
incremental cost per recurrence avoided and incremental 
cost per quality-adjusted life per year gained over 3 years 
and over long term through a modelling exercise over 
patients’ lifetime.
Ethics and dissemination Formal ethics review was 
undertaken with a favourable opinion, in line with UK 
regulatory procedures (REC reference number: 14/
NE/1062). If reductions in time to recurrence is associated 
with long-term patient benefits, the cost-effectiveness 
evaluation will provide further evidence to inform adoption 
of the technology. Findings will be shared in lay media 
such as patient and charity forums and will be presented 
at key meetings and published in academic literature. Trial 
registration number ISRCTN84013636.
bACkground
Bladder cancer is the most frequently 
occurring tumour of the urinary system.1 
Staging of bladder cancer is described using 
the tumour, node and metastasis system.2 
Tumours confined to the epithelial lining 
(urothelium) are classified as stage Ta, and 
those invading the lamina propria are classi-
fied as stage T1.
Ta and T1 tumours can be removed by trans-
urethral resection (TURBT) that involves 
passing a cystoscope through the urethra 
into the bladder and resecting the tumour 
under direct visualisation. For therapeutic 
purposes, Ta and T1 tumours are grouped 
together as non-muscle invasive bladder 
cancer (NMIBC). Grade (microscopic char-
acteristics of the tumour cells) can be used 
to describe aggressiveness of cancers and are 
characterised as either low grade (relatively 
benign) or high grade (aggressive). NMIBC 
also include flat, high-grade tumours that are 
strengths and limitations of this study
 ► The effectiveness of the photodynamic diagno-
sis (PDD) for the initial resection of intermediate 
and high risk non-muscle invasive bladder cancer 
(NMIBC) as part of routine care will be demonstrated 
with a pragmatic clinical trial design.
 ► Full-health economic evaluation will provide 
high-quality evidence of the burden of NMIBC for the 
National Health Service.
 ► A well-characterised trial associated biorepository 
of longitudinal serially collected tissue samples.
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confined to the epithelium classified as carcinoma in situ 
(CIS).2
Complete resection of the tumour with TURBT is 
essential to obtain good prognosis. It is thought that 
failure to identify satellite tumours or to appreciate 
the full extent of the tumours visualised during resec-
tion using conventional white light cystoscopy may be 
a factor in 20%–40% of recurrent bladder tumours.3 4 
Incomplete resection with TURBT is also associated with 
staging errors. In order to correct the staging errors asso-
ciated with initial TURBT, a second resection within 2–6 
weeks is suggested for select group patients.5 It has been 
postulated that development in cystoscopy imaging can 
improve resections and decrease the need for a second 
resection.6
Recurrence and stage progression to muscle invasive 
(T2–T4) or metastatic cancer is more likely to occur in 
those with high-grade tumours with concomitant CIS. 
CIS in particular can be easily missed using conventional 
white light-guided resection.6
Surveillance of NMIBC is carried out with cystoscopy 
to detect recurrence early and allow treatment before 
progression. Clinical guidelines tailor follow-up proto-
cols according to the risk groups (low, intermediate and 
high) developed using clinical and histological parame-
ters.7 Advised follow-up of low risk is at 3 months, and if 
negative, the next cystoscopy is scheduled for 9 months 
later and then yearly for 5 years. Patients with high-risk 
tumours have cystoscopy and urine cytology at 3 months. 
If negative, it is repeated every 3 months for 2 years, then 
every 6 months until 5 years and annually thereafter.5 The 
intensity of cystoscopic follow-up for patients with inter-
mediate risk is not clearly defined, for which a follow-up 
scheme in-between those described for low and high 
risk and is adapted according to personal and subjective 
factors.5
Photodynamic diagnosis (Pdd) of nMIbC
As an attempt to improve resection rates, PDD has been 
developed to enhance tumour detection and guide resec-
tion. A cystoscopy image of white light (WL) versus PDD is 
presented in figure 1. Meta-analyses and systematic reviews 
of PDD-guided treatment of NMIBC have shown efficacy 
in tumour detection and reduction in residual tumour 
compared with white light cystoscopy alone. These find-
ings translate into reduced recurrence rates.6 8 However, 
these trials were efficacy studies, and the systematic review 
called for a pragmatic study to allow better interpretation 
of possible benefit into daily clinical practice.
Health economics of nMIbC
NMIBC is one of the most costly cancers to manage on 
a per-patient basis because of its high prevalence, high 
recurrence rate, need for adjuvant treatments and the 
requirement for long-term cystoscopic surveillance. The 
total cost of treatment and 5-year follow-up of patients 
with NMIBC diagnosed in the UK has increased from 
£73 million to £213 million from 2001 to 2012 (inflation 
corrected).9 10 From a patient perspective, there often are 
considerable anxieties about recurrences, transurethral 
resection and progression, requiring additional therapies 
with potential mortality and long-term morbidity (eg, 
radical surgery). Transurethral resection itself is associ-
ated with reduced quality of life, including both mental 
and physical health domains, although these effects are 
usually transient.11 Substantial effects on health-related 
quality of life (HRQoL) are most likely to come from 
adjuvant intravesical treatments and radical or palliative 
treatments for progression.12 The cost-effectiveness of 
NMIBC treatment strategies has not been widely studied.
nMIbC biomarkers and clinical impact
To date, existing non-invasive commercial biomarkers 
(primarily urinary) are not embedded in routine clin-
ical practice due to poor sensitivity, specificity and lack 
of evidence. Several research bodies have recognised the 
lack of clinically useful biomarkers for bladder cancer. 
‘Fit for purpose’ sample resources accessible to high-
throughput ‘omic’ technologies will afford the greatest 
opportunity to generate translational hypotheses and 
ensure clinical validity and utility of putative candidate 
markers/signatures.13 14 Robust, ‘future-proof’, longi-
tudinal serial sample archives providing critical insights 
of the natural history of bladder cancer correlated with 
clinical detail for retrospective translational biomarker 
discovery are lacking.
Current research objectives
More efficient management strategies to reduce NMIBC 
recurrence and hence decrease both the burden to 
patients and costs are urgently needed. PDD-guided initial 
TURBT has been identified as a technique that can help 
achieve these aims. The objective of the current research 
(PHOTO trial) is to determine whether photodynamic 
surgery guided by a fluorescent tumour marker is better 
Figure 1 White light (A) and blue light (photodynamic) (B) 
cystoscopy image of the bladder from a patient diagnosed 
with CIS. On PDD, the area with CIS appears red, while 
with WL the area is unclear. CIS, carcinoma in situ; PDD, 
photodynamic diagnosis.
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than conventional white light surgery in the cystoscopic 
treatment of people with intermediate and high risk 
cancers confined to the bladder lining and whether its 
implementation is cost-effective. The trial includes a full 
assessment of the costs of patient management through 
the care pathway. Individual patient data from this trial 
will be used for subsequent mathematical modelling 
studies to investigate safe monitoring frequency. The 
photodynamic versus white light-guided treatment of 
NIMBC trial has the following research objectives:
Primary objectives
Clinical effectiveness: to compare time to recurrence 
for each of the two treatment strategies, with a principal 
point of interest at 3 years.
Cost-effectiveness: to evaluate cost-effectiveness as 
measured by the incremental cost per recurrence avoided 
and the cost-utility as measured by the incremental cost 
per quality-adjusted life year (QALY) gained at 3 years 
and over patients’ lifetime.
Secondary objectives
a. To measure relative rates of disease progression at 
3 years.
b. To measure relative harms and safety.
c. Patient lifetime HRQoL and cancer-specific survival.
Additional objectives
a. To model the safest and most cost-effective cystoscopic 
follow-up surveillance schedule.
b. To evaluate the learning curve for the procedure 
and account for its effects on outcomes of both PDD-
guided and standard white light resections.
c. To establish a well-characterised cohort of serial sam-
ples from patients with intermediate and high-risk 
NMIBC including clinical data, urine, blood and tu-
mour specimens for separately funded translational 
research.
MEtHods And dEsIgn
study design
PHOTO is a multicentre randomised open parallel group 
non-masked superiority trial comparing the intervention 
of PDD guided bladder tumour resection with standard 
white light resection in patients with newly diagnosed inter-
mediate and high risk NMIBC. Apart from initial treat-
ment, both groups will receive standard care, including 
single dose intravesical mitomycin C within 24 hours of 
initial resection, surveillance according to risk-adjusted 
schedules and adjuvant therapy as indicated by current 
practice guidelines. The target number of patients to be 
recruited is 533 with a trial specific follow-up of at least 
36 months for each individual. The outline of the study 
protocol (version 4, 2 February 2018) is shown in figure 2.
Intervention
The interventions being compared within PHOTO 
trial are: PDD-guided transurethral resection (TURBT) 
(experimental group) versus standard white light TURBT 
(control group).
All participants, unless there are clinical contra-indica-
tions, receive intravesical mitomycin C (40 mg in 40 mL 
saline), ideally within 6 hours following TURBT but 
otherwise within the inpatient setting before discharge.
Technique of PDD
PDD requires preliminary instillation of the photosensi-
tiser hexaminolevulinate (85 mg in 50 mL of phosphate 
buffered saline) into the participant’s bladder through 
a urethral catheter. Participants are asked not to pass 
urine for at least 1 hour after insertion. Following oper-
ating theatre preparation according to local standard 
procedures and under appropriate anaesthesia, partic-
ipants undergo TURBT of their bladder tumour under 
blue light (wavelength 380–450 nm) illumination of the 
bladder. The equipment required includes a specialised 
light source, cystoscope, light cables and cameras. When 
using PDD, normal bladder epithelium appears blue, 
while red areas should be considered suspicious and 
should be resected.
Technique of standard white light cystoscopy
The control group does not have any preliminary photo-
sensitiser instillation and undergo standard tumour 
localisation and resection under white light (wavelength 
400–800 nm) illumination of the bladder.
Participants
In the PHOTO trial, adult patients with a suspected new 
diagnosis of intermediate or high risk NMIBC are studied. 
Participants are identified prior to initial resection based 
on results of preliminary visual assessment via cystoscopy 
or imaging performed as part of standard evaluation for 
suspected urinary tract malignancy.
Patients with the following criteria are included in the 
PHOTO trial:
 ► Adult men and women aged ≥16 years.
 ► First suspected diagnosis of bladder cancer.
 ► Visual/ultrasound/CT diagnosis of intermediate/
high risk NMIBC.
 ► White light visual appearances of intermediate or 
high risk disease (≥3 cm or two or more tumours or 
flat velvety erythematous changes alerting a clinical 
suspicion of CIS).
OR
Suspicion of papillary bladder tumour ≥3 cm based on 
ultrasound or CT scanning (without hydronephrosis).
 ► Written informed consent for participation prior to 
any study specific procedures.
 ► Willing to comply with the following lifestyle 
guidelines:
 – Female participants must be surgically sterile or be 
postmenopausal or must agree to use effective con-
traception after joining the study and for 7 days af-
ter treatment. Female participants must not breast 
feed for 7 days after treatment.
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 – Male participants must be surgically sterile or must 
agree to use effective contraception after joining 
the study and for 7 days after treatment.
 – Effective contraception is defined as two forms of 
contraception, including one barrier method.
Exclusion criteria applied in the PHOTO trial are:
 ► Visual evidence of low risk NMIBC (solitary 
tumour <3 cm).
 ► Visual evidence of MIBC on preliminary cystoscopy, 
that is, non-papillary or sessile mass (attached directly 
by its base without a stalk).
 ► Imaging evidence of MIBC – CT/USS (this includes 
the presence of hydronephrosis, which may be present 
despite clear imaging of MIBC in the bladder).
 ► Upper tract (kidney or ureteric) tumours on imaging.
 ► Any other malignancy in the past 2 years (except: 
non-melanomatous skin cancer cured by excision, 
adequately treated CIS of the cervix, Ductal carcinoma 
in situ (DCIS)/ Lobular carcinoma in situ (LCIS) of 
the breast or prostate cancer in patients who have a 
life expectancy of >5 years on trial entry).
 ► Evidence of metastases.
 ► Porphyria or known hypersensitivity to porphyrins.
 ► Known pregnancy (based on history and without 
formal testing, in keeping with day-to-day National 
Health Service (NHS) practice of PDD use).
 ► Any other conditions that in the principal inves-
tigator’s opinion would contraindicate protocol 
treatment.
 ► Unable to provide informed consent.
Figure 2 PHOTO trial study design summary.
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 ► Unable or unwilling to complete follow-up schedule 
(including HRQoL questionnaires).
Informed consent-ethics approval
The study complies with the Helsinki Declaration and the 
principles of Good Clinical Practice.
Potential participants are identified mainly through 
rapid access haematuria clinics at participating sites from 
the UK. An eligibility checklist is completed by the local 
principal investigator (or delegate) to assess fulfilment of 
the entry criteria for all patients considered for the study. 
Information from the diagnostic cystoscopy is used to 
assess eligibility.
All potentially eligible patients are provided with 
an information sheet to explain why they have been 
approached and the nature of the study. Eligible patients 
are asked to provide written informed consent for the 
study only after they have had sufficient time to consider 
the trial and had the opportunity to have any further 
questions addressed.
recruitment and randomisation
Eligible patients are centrally randomised using either 
the secure web-based or the 24-hour interactive voice 
response randomisation system at the Centre for Health-
care Randomised Trials in Aberdeen, using minimisation 
by centre and gender, to allocate participants 1:1 to the 
control and experimental groups. The minimisation algo-
rithm incorporates a random element in order to prevent 
deterministic treatment allocation. The trial was opened 
on the 23 October 2014 and recruitment was completed 
on 14 February 2018. Over this period, 22 centres joined 
the study and contributed to recruitment. List of sites 
participating are available on http://www. isrctn. com/ 
ISRCTN84013636.
outcome measures
Primary outcome measures
Clinical effectiveness: time to recurrence is measured as 
time from randomisation to first recurrence.
Cost effectiveness: a health economic model will be 
developed to calculate incremental cost per recurrence 
avoided and incremental cost per QALY gained over 
3 years.
Secondary outcome measures
Clinical effectiveness:
 ► Adverse events and complications up to 3 months 
from initial or second TURBT are captured and will 
be included in analysis.
 ► HRQOL is captured for each participant at base-
line (prior to knowledge of treatment allocation), 
following surgery and at 3, 6, 12, 18, 24 and 36 months 
after randomisation.
 ► Disease progression is captured within the trial time. 
Patient lifetime projections will be made by using the 
trial data at baseline and supplementing as necessary 
from other published data.
 ► Overall survival and bladder cancer-specific survival 
will be compared between the two treatment arms. 
Minimum follow-up of the last included patient will 
be 3 years and maximum expected follow-up is 66 
months.
Cost effectiveness:
 ► Estimation of the incremental cost per recurrence 
avoided using the economic model over the patients’ 
lifetime.
 ► Estimation of the incremental cost per QALY gained 
using the economic model over the patients’ lifetime.
Additional outcomes measures
Schedules for follow-up: using data from within the trial 
and, if appropriate, from other relevant sources, the risk 
of recurrence at each interval surveillance cystoscopy will 
be described to then model the most safe and efficient 
surveillance follow-up schedule.
The effect of PDD guided resection experience 
(learning curve) on clinical effectiveness: a subgroup 
analysis comparing outcomes from PDD-experienced 
and PDD-naïve surgeons (determined at baseline) will 
be conducted. Also for PDD-naïve surgeons, an assess-
ment of learning curve will be undertaken by comparing 
increasing experience and recurrence, in both PDD and 
WL resections.
tracking and monitoring adverse events
Direct surgically related postoperative events occurring 
within 30 days following the first TURBT or second 
TURBT if required will be assessed using The Clavien 
Dindo classification for surgical complications. Events 
occurring up to 3 months after TURBT (second TURBT 
if required) will be assessed and recorded using the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events V.4.0 framework (http:// ctep. cancer. 
gov/).15
trial assessment and measures
PHOTO trial schedule of assessment and investigations 
are summarised in table 1. Routine attendances for diag-
nosis and staging of new bladder cancers are used to 
establish eligibility, which includes obtaining the medical 
history. Eligible patients who consent for the trial are 
administered HRQoL questionnaires prior to primary 
TURBT and prior to discharge.
Time to recurrence will be measured from the day 
of randomisation to the day of subsequent biopsy with 
pathologically proven recurrence. Data will be collected 
from the following routine visits; 3, 6, 9, 12, 18, 24 and 
36 months postinitial TURBT (or second TURBT if 
required). Associated costs and changes in HRQoL will 
be measured. These will be collected by postal question-
naires sent directly to participants at 3, 6, 12, 18, 24 and 
36 months postrandomisation.
Disease progression will be assessed using results of 
further resection or imaging during follow-up. Progres-
sion will be defined as increase of stage into MIBC or 
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development of nodal or metastatic disease. In addition, 
patients showing failure to respond to intravesical treat-
ment (eg, BCG failure) will also be captured.
The relative changes in HRQoL resulting from the phys-
ical and psychological benefit together with any harms 
associated with each strategy and with subsequent neces-
sary cancer treatment will be measured using the generic 
EQ-5D-3L questionnaire, cancer-specific European Orga-
nization for Research and Treatment of Cancer Quality of 
Life Questionnaire Version 3.0 (EORTC-QLQ-C30) and 
disease-specific European Organisation for Research and 
Treatment of Cancer (EORTC) Quality of Life Question-
naire for Non-Muscle-Invasive Bladder Cancer (EORTC 
QLQ-NMIBC24) questionnaire completed by the 
participant.
Effect of PDD-guided resection experience on clin-
ical effectiveness: all recruiting surgeons will complete 
a learning curve questionnaire to elicit their white light 
and PDD resection experience prior to any recruitment. 
The subsequent accruing experience of each surgeon will 
be captured on case report forms. Early recurrence (12 
weeks) will be used as a proxy of incomplete resection.
sample size
We aim to detect an absolute reduction in recurrence at 
3 years of 12%: from 40% (under the conservative assump-
tion that all the patients recruited are intermediate risk 
patients with a probability of recurrence of 0.4 at 3 years) 
to 28% (similar effect sizes of photodynamic therapy are 
reported in both intermediate and high risk groups), this 
will be equivalent to a relative reduction of 30%.
Recruitment of 533 participants (214 recurrences) will 
detect an HR of 0.64 between experimental and control 
strategies and provide, using the log-rank test, 90% power 
at a two-sided 5% significance level. This calculation 
assumes 2.5 years incremental recruitment, a minimum 
of 3-year follow-up and a 6.4% follow-up attrition at end 
of year three. To achieve this, we plan to use 30 secondary 
care sites that would see new bladder cancers diagnoses, 
from which we will exclude patients with MIBC (20%) 
and, from the remaining NMIBCs, exclude low risk 
disease (50%). Furthermore, we predict only 30% of 
these patients will be recruited based on willingness to 
participate or missed opportunities for recruitment.
Health economics analysis
A within-trial cost-effectiveness analysis will be conducted 
to calculate incremental cost per recurrence avoided and 
incremental cost per QALY gained over 3 years. Data on 
costs, recurrence and QALYs for each participant will 
be recorded in the trial and used to estimate mean cost, 
recurrence and QALYs for each intervention group. As 
the time horizon of the trial is 3 years, these data will be 
discounted at 3.5%.16 The cost, recurrence avoided and 
QALY data will then be used to estimate incremental 
costs, recurrence avoided and QALYs and incremental 
cost per recurrence avoided and incremental costs per 
QALY.
An economic model will be developed to estimate rela-
tive rates of cost-effectiveness and cost–utility, at 3 years 
(to mirror the within trial analysis) and over a patient life-
time time horizon. An perspective will be taken for the 
cost calculations. The model takes the form of a Markov 
state transition model that describes the consequences of 
different diagnosis and treatment strategies in terms of 
clinical and cost outcomes.6 The rates of recurrence and 
progression recorded with the 3-year follow-up of the trial 
will be used to model short-term recurrence and progres-
sion rates. Further data required for the model relates to 
the transition and other probabilities of events beyond 
the 3-year follow-up, including the risk of recurrence 
and progression, probabilities of receiving different 
types of intervention should progression or recurrences 
occur and risks of mortality (both from bladder cancer 
and other causes), will be sought through a structured 
systematic review of long-term outcomes of treatments 
of bladder cancer. The model will be used to produce 
estimates of costs, QALYs, recurrence rates and survival. 
Both costs and outcomes will be discounted at 3.5% in 
the base case analyses. Cost-effectiveness will be reported 
as incremental cost per QALY gained and incremental 
cost per recurrence avoided (at both 3 years and over the 
patient’s lifetime). These data will be presented as point 
estimates and bootstrapping techniques will be used to 
estimate the statistical imprecision surrounding them. 
The results of this stochastic analysis will be presented 
as cost and QALY plots and as cost-effectiveness accept-
ability curves. Further deterministic sensitivity analyses 
will be conducted to explore other forms of uncertainty, 
for example, surrounding the choice of discount rate 
or around the unit costs of equipment. The model will 
be probabilistic, and distributions will be attached to all 
parameters, and the shape and type of distribution will 
depend on the data available and recommendations for 
good practice in modelling.17
Patient and public involvement
Patient involvement was ensured at the early stages of 
protocol development and contributed to user-lead devel-
opment of outcomes of value to patients in the design of 
the trial. Additionally, the patient journey of patient repre-
sentatives was investigated through the diagnosis and 
treatment of bladder cancer, which includes an anony-
mised account impact on his quality of life. This helped 
understand the burden of the intervention on patients. A 
patient representative was involved as a coinvestigator and 
member of the trial steering committee helping manage 
and analyse the implications of the research.
PHoto translational (PHoto-t) side study
PHOTO-T aims to establish a well-characterised trial 
associated biorepository of longitudinal serially collected 
tissue samples (blood, urine and FFPE). The collection 
of samples from PHOTO patients is optional with every 
PHOTO-T consented participant collecting a urine and 
blood sample at baseline (pre-treatment/TURBT) and 
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3, 12, 24 and 36 months treatment follow-up or at recur-
rence (whichever comes first, predicted at 70% for the 
highest risk group over a trial period of 3 years). A FFPE 
core at baseline (plus recurrence, if occurs) will also be 
collected (online supplementary).
dIsCussIon
Bladder cancer is the most frequent urothelial cancer, 
and the overall costs for treatment and follow-up 
remain higher than most other cancers.18 Achieving 
complete resection of NMIBC with TURBT is associated 
with lower recurrence rates in follow-up. However, it is 
unclear if this translates into lower progression rates 
in long-term follow-up. PDD-guided initial TURBT is a 
technology that could improve resection and ultimately 
reduce recurrence and the need for further treatments.
Studies on PDD have demonstrated the efficacy of the 
technology using strict study entry requirements, for 
which translation into daily clinical practice is limited. 
Therefore, in the PHOTO trial, the effectiveness of the 
technology as part of routine care will be demonstrated 
with a pragmatic clinical trial design.
PHOTO trial includes measurement of HRQoL using 
EQ-5D at the time of initial treatment and surveillance. 
The measurement of HRQoL around the time of the 
cystoscopy and TURBT can be particularly dynamic 
due to an acute deterioration in health score associ-
ated with the invasive procedure followed by a typical 
rapid recovery.11 19 Therefore, a side study was devel-
oped, where patients are recruited from the PHOTO 
trial to evaluate the acute deterioration in quality of life 
by suspected diagnosis or TURBT around the time of 
resection. This side study will use a time trade off exer-
cise, and the outcomes will supplement the calculation 
of QALYs in the health economic model.
The high costs of bladder cancer to healthcare 
systems has usually been obtained from weak data, 
and the true costs are unclear. The pragmatic design 
of the PHOTO trial alongside the robust data collec-
tion for a full health economic evaluation will provide 
high-quality evidence of the burden of NMIBC for the 
NHS. Moreover, it will also provide a cost-effectiveness 
comparison of white light versus PDD-guided initial 
TURBT resections.
Evidence on the required cases for PDD-naïve 
surgeons to gain competency the technology is weak. 
This could act as a potential confounder on the clinical 
outcomes measured and therefore will be accounted 
for during analysis. Moreover, an evaluation of the 
learning curve of PDD will also be carried out using the 
forms filled in by surgeons.
The primary outcome of the study is time to recur-
rence measured from the day of randomisation to 
the day of subsequent biopsy with pathologically 
proven recurrence. If decrease in time to recur-
rence is associated with long-term patient benefits, 
the cost-effectiveness evaluation will provide further 
evidence for the NHS to decide on full adoption of the 
technology.
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